Antihypertensive effect of trimepranol, a new beta-blocking agent

Area of Science:

• Pharmacology
• Cardiovascular Medicine

Background:

• Hypertension remains a significant global health concern.
• Non-selective beta-adrenoreceptor blocking drugs are established antihypertensive agents.

Purpose of the Study:

• To evaluate the antihypertensive efficacy of Trimepranol (TMP) compared to placebo.
• To assess the safety and tolerability of TMP in hypertensive patients.

Main Methods:

• A double-blind, placebo-controlled, cross-over study design was employed.
• Twenty-five ambulatory patients with supine diastolic blood pressure (BP) ≥ 95 mm Hg participated.
• Trimepranol dosage was titrated, followed by six-week treatment periods of TMP and placebo.

Main Results:

• Trimepranol significantly reduced supine systolic BP (156 to 140 mm Hg) and diastolic BP (105 to 93 mm Hg) (p < 0.001).
• 19 out of 25 patients achieved a supine diastolic BP below 95 mm Hg with TMP.
• A correlation was observed between TMP's antihypertensive and bradycardic effects; mild side effects were noted.

Conclusions:

• Twice-daily Trimepranol is an effective antihypertensive medication.
• TMP demonstrates a favorable efficacy profile in managing elevated blood pressure.
• Further research may explore long-term effects and optimal dosing.